Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Middle East Conflict Impacts Australia and New Zealand Businesses 
WESTLAKE VILLAGE, Calif., May 02, 2018 -- MannKind Corporation (Nasdaq:MNKD) will release its 2018 first quarter financial results on Wednesday, May 9, 2018 and its management will host a conference call to discuss the financial results and other Company developments at 5:00 PM (Eastern Time) on May 9, 2018.
Presenting from the Company will be its Chief Executive Officer, Michael Castagna, Chief Financial Officer, Steven Binder, Chief Commercial Officer, Pat McCauley and Chief Medical Officer, David Kendall.
To view and listen to the earnings call webcast live via the Internet, visit the Company's website at www.mannkindcorp.com and click on the “Q1 2018 MannKind Earnings Conference Call” link in the Webcasts section of News & Events. To participate in the live call by telephone, please dial (800) 289-0438 toll-free or (323) 794-2423 toll/international and use the conference passcode: 3321662.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 toll-free or (412) 317-6671 toll/international and use the replay passcode: 3321662. A replay will also be available on MannKind's website for 14 days.
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
[email protected]
